Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 18: | Line 18: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT | ||
|- | |- | ||
! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders | ! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders | ||
Line 37: | Line 37: | ||
| align="center" style="background:#F5F5F5;" | ↓ | | align="center" style="background:#F5F5F5;" | ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
Line 61: | Line 61: | ||
| align="center" style="background:#F5F5F5;" | ↓ | | align="center" style="background:#F5F5F5;" | ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication. | | align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication. | ||
|- | |- | ||
Line 78: | Line 78: | ||
| align="center" style="background:#F5F5F5;" | ↓ | | align="center" style="background:#F5F5F5;" | ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]]. | | align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]]. | ||
Line 94: | Line 94: | ||
| align="center" style="background:#F5F5F5;" | ↓ | | align="center" style="background:#F5F5F5;" | ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
Line 110: | Line 110: | ||
| align="center" style="background:#F5F5F5;" | ↓ | | align="center" style="background:#F5F5F5;" | ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
Line 132: | Line 132: | ||
| align="center" style="background:#F5F5F5;" | ↓ | | align="center" style="background:#F5F5F5;" | ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
Line 154: | Line 154: | ||
| align="center" style="background:#F5F5F5;" | ↓ | | align="center" style="background:#F5F5F5;" | ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
Line 180: | Line 180: | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl or ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
Line 197: | Line 197: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
| align="center" style="background:#F5F5F5;" | Rare | | align="center" style="background:#F5F5F5;" | Rare | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl or ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* AR inheritance | * AR inheritance | ||
Line 216: | Line 216: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl or ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* AR inheritance | * AR inheritance | ||
Line 236: | Line 236: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl or ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* Anti-WASP antibody can be used to detect presence or absence of WAS protein | * Anti-WASP antibody can be used to detect presence or absence of WAS protein | ||
Line 259: | Line 259: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl or ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* AD inheritance | * AD inheritance | ||
* | * AbNlities of platelet granule formation | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | ||
Line 279: | Line 279: | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl or ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
Line 301: | Line 301: | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types. | | align="center" style="background:#F5F5F5;" | See the table below for the details about different types. | ||
|- | |- | ||
Line 327: | Line 327: | ||
| − | | − | ||
| − | | − | ||
| | |Nl | ||
|↑ | |Nl or ↑ | ||
| | |Nl | ||
| | |Nl | ||
| | |Nl | ||
|− | |− | ||
|- | |- | ||
Line 348: | Line 348: | ||
| − | | − | ||
| − | | − | ||
| | |Nl | ||
|↑ | |Nl or ↑ | ||
| | |Nl | ||
| | |Nl | ||
| | |Nl | ||
|− | |− | ||
|- | |- | ||
Line 375: | Line 375: | ||
* [[Bleeding]] from the [[umbilical cord]] stump after birth | * [[Bleeding]] from the [[umbilical cord]] stump after birth | ||
* Bleeding after [[dental surgery]] or tooth extraction | * Bleeding after [[dental surgery]] or tooth extraction | ||
* | * AbNl bleeding during or after injury, surgery, or childbirth | ||
* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]] | * [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]] | ||
Line 386: | Line 386: | ||
|± | |± | ||
| + | | + | ||
| | |Nl | ||
|↑ | |↑ | ||
|↑ | |↑ | ||
Line 412: | Line 412: | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | |Nl | ||
| | |Nl | ||
|↑ | |↑ | ||
|↑ | |↑ | ||
Line 433: | Line 433: | ||
| + | | + | ||
| + | | + | ||
| | |Nl | ||
|↑ | |↑ | ||
|↑ | |↑ | ||
|↑ | |↑ | ||
| | |Nl | ||
|The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding. | |The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding. | ||
|- | |- | ||
Line 454: | Line 454: | ||
| + | | + | ||
| + | | + | ||
| | |Nl | ||
| | | | ||
|↑ | |↑ | ||
| | |Nl | ||
| | |Nl | ||
|Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy | |Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy | ||
|- | |- | ||
Line 480: | Line 480: | ||
| + | | + | ||
| + | | + | ||
| | |Nl | ||
| | |Nl | ||
|↑ | |↑ | ||
|↑ | |↑ | ||
| | |Nl | ||
|− | |− | ||
|- | |- | ||
Line 498: | Line 498: | ||
|_ | |_ | ||
|_ | |_ | ||
| | |Nl | ||
| | |Nl | ||
| | |Nl | ||
|↑ | |↑ | ||
| | |Nl | ||
| | | | ||
|- | |- | ||
Line 514: | Line 514: | ||
|_ | |_ | ||
|_ | |_ | ||
| | |Nl | ||
| | |Nl | ||
| | |Nl | ||
|↑ | |↑ | ||
| | |Nl | ||
| | | | ||
|- | |- | ||
Line 530: | Line 530: | ||
|_ | |_ | ||
|_ | |_ | ||
| | |Nl | ||
| | |Nl | ||
| | |Nl | ||
|↑ | |↑ | ||
| | |Nl | ||
| | | | ||
|- | |- | ||
Line 549: | Line 549: | ||
|± | |± | ||
|± | |± | ||
| | |Nl | ||
| | |Nl | ||
| | |Nl or ↑ | ||
| | |Nl | ||
| | |Nl | ||
| | | | ||
* Impaired fibrin cross linking or clot dissolution | * Impaired fibrin cross linking or clot dissolution | ||
Line 574: | Line 574: | ||
| + | | + | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | |Nl | ||
| | |Nl | ||
| | |Nl | ||
|↑ | |↑ | ||
| | |Nl | ||
|− | |− | ||
|- | |- | ||
Line 593: | Line 593: | ||
| + | | + | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | |Nl | ||
| | |Nl | ||
| | |Nl | ||
|↑ | |↑ | ||
| | |Nl | ||
|− | |− | ||
|- | |- | ||
Line 610: | Line 610: | ||
|Rare | |Rare | ||
|Rare | |Rare | ||
| | |Nl | ||
| | |Nl | ||
| | |Nl | ||
|↑ | |↑ | ||
| | |Nl | ||
| − | | − | ||
|- | |- | ||
Line 637: | Line 637: | ||
|↑ | |↑ | ||
|↑ | |↑ | ||
| | |Nl | ||
| − | | − | ||
|- | |- | ||
Line 657: | Line 657: | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | |Nl | ||
|↑ | |↑ | ||
|↑ | |↑ | ||
| | |Nl or mildly prolonged | ||
| | |Nl | ||
| − | | − | ||
|} | |} |
Revision as of 15:59, 19 October 2018
Differential Diagnosis
Different causes of the bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.
These features have discussed in the below table:
Category | Sub-category | Diseases | History | Clinical manifestation | Laboratory testing | Comments | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | ||||||
Platelet disorders | Thrombocytopenia | Infection-Induced thrombocytopenia |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |
Medications-Induced thrombocytopenia |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | Most important part of treatment is discontinuing of the medication. | |||
Heparin-Induced thrombocytopenia |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | ↑ | For more information click here: Heparin-induced thrombocytopenia. | |||
Immune Thrombocytopenic Purpura (ITP) |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Inherited Thrombocytopenia |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Thrombotic Thrombocytopenic Purpura (TTP) | History of:
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Hemolytic Uremic Syndrome | History of: | + | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Thromobcytosis | Iron deficiency anemia
Inflammatory diseases |
− | − | − | − | ± | ± | ↑ | Nl or ↑ | Nl | Nl | Nl | − | |||
Qualitative Disorders of Platelet Function | Inherited Disorders of Platelet Function | Glanzmann’s thrombasthenia |
|
+ | + | + | + | − | Rare | Nl or ↓ | ↑ | Nl | Nl | Nl |
| |
Bernard-Soulier syndrome |
|
+ | + | + | + | − | − | Nl or ↓ | ↑ | Nl | Nl | Nl |
| |||
Wiskott-Aldrich syndrome |
|
+ | + | + | + | − | − | Nl or ↓ | ↑ | Nl | Nl | Nl | ||||
Platelet storage pool disorder (SPD): |
|
+ | + | + | + | − | − | Nl or ↓ | ↑ | Nl | Nl | Nl |
| |||
Acquired Disorders of Platelet Function |
|
+ | + | + | + | ± | ± | Nl or ↓ | ↑ | Nl | Nl | Nl | − | |||
Von Willebrand Disease |
|
+ | + | + | + | ± | ± | ↑ | Nl | ↑ | ↑ | Nl | See the table below for the details about different types. | |||
Vessel wall disorders | Metabolic and Inflammatory Disorders |
|
|
− | + | + | ± | − | − | Nl | Nl or ↑ | Nl | Nl | Nl | − | |
Inherited Disorders of the Vessel Wall |
|
− | + | + | ± | − | − | Nl | Nl or ↑ | Nl | Nl | Nl | − | |||
Coagulation factor disorders | Fibrinogen deficiency | Different types of the fibrinogen disorders: |
|
− | − | + | + | ± | + | Nl | ↑ | ↑ | ↑ | ↑ |
| |
Prothrombin deficiency |
|
− | + | + | + | + | + | Nl | Nl | ↑ | ↑ | ↑ | − | |||
Factor V deficiency |
|
− | _ | + | + | + | + | Nl | ↑ | ↑ | ↑ | Nl | The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding. | |||
Factor VII deficiency |
|
+ | + | + | Nl | ↑ | Nl | Nl | Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy | |||||||
Factor X deficiency |
|
+ | + | + | + | + | Nl | Nl | ↑ | ↑ | Nl | − | ||||
Factor XII deficiency |
|
_ | _ | _ | _ | _ | Nl | Nl | Nl | ↑ | Nl | |||||
High molecular weight kininogen (HMWK) deficiency |
|
_ | _ | _ | _ | _ | Nl | Nl | Nl | ↑ | Nl | |||||
Prekallikrein deficiency |
|
_ | _ | _ | _ | _ | Nl | Nl | Nl | ↑ | Nl | |||||
Factor XIII deficiency | Types:
|
|
± | ± | ± | ± | ± | ± | Nl | Nl | Nl or ↑ | Nl | Nl |
| ||
Hemophilia | Type A deficiency |
|
− | − | − | + | + | + | Nl | Nl | Nl | ↑ | Nl | − | ||
Type B deficiency |
|
− | − | − | + | + | + | Nl | Nl | Nl | ↑ | Nl | − | |||
Type C deficiency |
|
− | − | − | + | Rare | Rare | Nl | Nl | Nl | ↑ | Nl | − | |||
Rare diseases | Disseminated Intravascular Coagulation |
|
+ | + | + | + | + | + | ↓ | ↑ | ↑ | ↑ | Nl | − | ||
Vitamin K Deficiency |
|
+ | − | + | + | + | + | Nl | ↑ | ↑ | Nl or mildly prolonged | Nl | − |
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:
Type of VWD | Type of factor deficiency | Prevalence | Inheritance pattern | Clinical manifestations | VWF activity | RIPA | Factor VIII | |
---|---|---|---|---|---|---|---|---|
Type 1 | Quantitative/ partial | 60-70% | AD |
|
↓ | ↓ | ↓ | |
Type 2 | 2A | Qualitative | 10% | AD/AR |
|
↓ | ↓ | N or ↓ |
2B | Qualitative | 5% | AD |
|
↓ | ↑ | N or ↓ | |
2M | Qualitative | <1% | AD/AR |
|
↓ | ↓ | N or ↓ | |
2N | Qualitative | <1% | AR |
|
N | N | ↓ | |
Type 3 | Complete deficiency | 1-2% | AR |
|
Absent | ↓ | Low, 1-10% |
For more information on Von Willebrand disease, click here.
- ↑ Invalid
<ref>
tag; no text was provided for refs namedpmid28966616